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Heparan sulfate proteoglycans (HSPGs) are essential components of the glomerular basement mem­
brane (GBM) carrying a strong anionic charge. A well-characterized extracellular HSPG is perlecan, 
ubiquitously expressed in basement membranes. A cDNA construct encoding domains I and II of human 
perlecan was expressed as a fusion protein with glutathione S-transferase. This fusion protein was used 
to generate monoclonal antibody 95J 10. We compared the staining pattern of 95J10 with that of M215, 
a previously prepared mAb that recognizes HSPG isolated from human GBM. In kidney cortex, the anti- 
perlecan mAh 95J10 showed a strong staining of the mesangium, Bowman’s capsule, the tubular basement 
membrane, and stained the GBM only slightly. In contrast, M215 predominantly stained the GBM in a 
linear fashion, lmmunoeleclron microscopy supported these results, showing concentrations of perlecan 
in some regions of the GBM, whereas the unidentified M215 antigen was homogenously distributed 
throughout the GBM. In other human tissues, both antibodies also produced a different staining pattern. 
Furthermore, a polyclonal antiserum recognizing HSPG isolated from the GBM did not recognize per­
lecan from El IS tumors. These results provide evidence for the presence of another HSPG in the GBM 
that is immunologically distinct from perlecan, The absence of perlecan splice variants in the kidney 
suggests that this component is encoded by a different gene than perlecan. Given its marked expression 
in the GBM, I his component could be a determining factor in the maintenance of selective glomerular 
permeability.
Keywords: perlecan; heparan sulfate proteoglycan; prokaryotic expression; glomerular basement mem­
brane.
The glomerular basement membrane (GBM) is a specialized 
extracellular matrix located at the interface of the glomerular 
visceral epithelium and the vascular endothelium. The GBM 
provides a rigid structure that supports the tissue to withstand 
high local blood pressure, its mechanical strength being en­
hanced by the highly organized interplay of its biopolymer com­
ponents | e.g. collagen IV, I ami n in, nidogen, and heparan sulfate 
proteoglycan (HSPGs)| [ 11. Another crucial function of the 
GBM is to regulate the passage of proteins depending on their 
molecular size and charge |2|. The impermeability of the GBM 
for anionic macromolecules is assigned to the presence of 
HSPGs anchored within it. The electrostatic charge of these 
HSPGs can be visualized by electron microscopy using cationic 
crritin |2) or heparan sulfate (TlS)-specific mAbs |3J. The signi­
ficance of tliis mechanism was demonstrated by perfusing rat
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Abbreviations. GBM, glomerular basement membrane; GST, gluta­
thione .V-transleraso; MS, heparan sulfate; HSPG, heparan sullate pro­
teoglycan.
Enzymes. Glutathione transferase (HO 2.5.1.18); DNA ligase (ATP) 
(EC 6.5.1.1); thrombin (HC 3.4.21.5); type II site-specific deoxyribonu­
clease (HC 3.1.21.4).
kidney with heparitinase, which resulted in leakage of anionic 
tracer proteins [4], A similar effect was observed when the kid­
ney was perfused with anti-HS mAbs [5]. Alterations in the HS 
content of the GBM causing nephrotic syndrome are involved 
in, for example, minimal change nephropathy, glomerulonephri­
tis, diabetes mellitus, and Denys-Drash syndrome [6- 8],
For biochemical characterization, HSPGs were extracted 
from isolated glomeruli [9], from epithelial cell lines [10], or 
from the mouse Engelbreth-HoIm-Swarm sarcoma [11 — 13]. Ex­
traction of HSPG from basement membranes is complicated clue 
to its strong interactions with other components. In addition, 
their analysis is confused by their smeared appearance on pro­
tein gels and their sensitivity to proteolysis. The first basement 
membrane proteoglycan characterized was termed perlecan, with 
reference to its beads-on-a-string-like appearance in rotary shad­
owing electron microscopy [14]. It consists of a 467-kDa core 
protein carrying five functional domains and three HS chains 
attached in close proximity to its N-terminus [15-17], Human 
perlecan is expressed by a single gene, named HSPG2, located 
on the short arm of chromosome 1 [18—20]. Several observa­
tions have suggested the presence of additional basement mem­
brane HSPGs: low-density forms (representing perlecan) and 
high-density forms characterized by relatively small core pro­
teins (18 —143 kDa) [21, 22]. However, it was demonstrated that 
these high-density proteoglycans are immunologically related to
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peiiecan, suggesting that they are generated by proteolytic pro­
cessing [23].
Previous immunofluorescence studies performed with vari­
ous polyclonal and monoclonal antibodies yielded inconsistent 
results, with particular differences in the staining intensity of the 
GBM [3, 9, 11, 24, 25]. For the generation of mAbs, prokaryotic 
expression offers a large advantage over proteoglycan extraction 
from basement membranes, because the risk of co-immunization 
with contaminating HSPG species is eliminated. Furthermore, 
recombinant protein expression allows the development of do­
main-specific antibodies. We have synthesized domains I and II 
of human perlecan as a bacterial fusion protein and generated 
monoclonal antibody 95J10. In this study, we compare the ex­
pression pattern in human tissues for 95J10 and M215, a mAb 
that was previously raised against isolated human GBM-HSPG 
[3], The results provide evidence for the presence of an uniden­
tified HSPG in the GBM, which appears to be immunologically 
distinct from perlecan.
EXPERIMENTAL PROCEDURES
Materials. The following were obtained from the indicated 
sources: pGEX4T-3 expression vector, glutathione-conjugated 
Sepharose 4B (Pharmacia Biotech); reduced glutathione (Boeh- 
ringer Mannheim), pCR-Script cloning vector, SrjI (Stratagene 
Cloning Systems); isopropylthio-/?-D-galactoside, T4 DNA li- 
gase, Ncol, BamUl (Life Technologies); Vent polymerase, Notl, 
Xcml (New England Biolabs); thermal cycler apparatus (Perkin 
Elmer); automated sequencer (Applied Biosystems); thrombin, 
phenylmethylsulfonyl fluoride, ribonuclease A (Sigma), 2- 
iodoacetamide (Merck); N-ethylenemaleimide, HDTA (Fluka 
Chemie); benzamidine hydrochloride (Janssen Chimica); 6- 
aminohexanoic acid (Aldrich); Tween-20 (ICN Biomedicals); 
Immobilon-P, ultrafiltration units (Millipore); goat-anti-mouse 
peroxidase conjugate (Dakopatts); sheep-anti-mouse fluorescein 
isothiocyanate conjugate (Cappel, Oss, The Netherlands); [y- 
32P]ATP, ECL detection kit (Amersham).
Construction of the expression vector pGEX4T3-P12a. A 
prokaryotic expression vector encoding amino acids 24—404 of 
human perlecan was prepared as follows. Two PCR products 
were generated from cDNA clone Hpe2 [16] using Vent poly­
merase for proofreading activity. The primer sets were: 5'-TCA-
TCTCCAGCGGCTCTGT-3' (forward PI), 5'-TCATGGGAAC- 
TGGGGCACTGTGC-3' (reverse PI), 5'~TCATCTCCAGCGG- 
CTCTGT-3' (forward P2) and 5'-TTACATGCAGCCAAACTC-
GTC-3' (reverse P2, this primer introduces an in-frame stop co­
don immediately behind amino acid 404). The two PCR prod­
ucts were inserted into the Srfl cloning site of pCR-Script [26, 
27] and screened to detect the unique Notl site at the 3'-end of 
the cDNA fragments. The P2 fragment was then ligated to the 
PI fragment by use of the Xcml restriction site, introduced into 
pGEX4T-3 [28] using the Ncol and Notl cloning sites. The fidel­
ity of amplification and ligation procedures was checked by se­
quence analysis. The resulting expression vector was named
pGEX4T3-P12a.
Expression and purification of recombinant perlecan- 
(24-404)-peptide. Expression of the recombinant perlecan- 
(24—404)-peptide was performed as described in [28], except 
that the cell pellet was resuspended in 125 ml ice-cold NaG/P*
(140 mM NaCl, 2.7 mM KC1, 10 mM Na2HP04, 2 mM KH2P0<, 
pH 7.5), 1% Triton X-100, 10 mM N-ethylmaleimide, 5 mM 
EDTA, 10 mM 6-aminohexanoic acid, 5 mM 2-iodoacetamide, 
1 mM phenylmethylsulfonyl fluoride and 1 mM benzamidine/ 
HC1. Cell lysis and affinity purification of the recombinant fu­
sion protein were performed in the presence of 1% Triton X-
100, which was essential for optimal yields. In contrast, the yield 
could not be improved by other modifications of the procedure 
such as the use of sarkosyl for solubilization [29], growth at 
30°C [30] or treatment with Mg2H and ATP prior to affinity
chromatography [31].
Affinity-purified fusion protein was incubated with 1.7 NIH 
U/ml human thrombin (specific activity approximately 4000 
NIH U/mg) and incubated for 60 min at 22°C. To exhaustively 
remove the thrombin-digested mixture from the glutathione S- 
transferase (GST) fragment, it was dialysed against NaCl/Pj to 
remove free glutathione and passed through a glutathione-conju­
gated Sepharose 4B column (1 ml) at room temperature. The 
flow-through was concentrated by ultrafiltration against a 10- 
kDa cutoff membrane to a final concentration of 0.63 mg/ml 
(determined by the Bradford method with BSA as reference)
[32].
Antibodies. The anli-perlecan mAb 95J10 was prepared as 
follows. Mice were immunized and boosted with 20 jag purified 
perlecan-(24-404)-peptide per injection (this preparation was 
completely devoid of GST). Iiybridoma cell lines were screened 
by ELISA with an independently isolated batch of recombinant 
fusion protein. Twelve positive clones were examined in indirect 
immunofluorescence studies for their capacity to stain human 
renal basement membranes. A mAb designated 95J 10 was se­
lected that showed strong glomerular staining. The mAh also 
reacted in western blot analysis with the fusion protein and with 
perlecan-(i-404)-peptide expressed by baculovirus-infected in­
sect cells [33], which indicated that it also recognizes the antigen 
in a denatured conformation. No cross-reactivity of mAb 95J'10 
with Escherichia coli proteins or GST was observed by ELISA 
and western blotting. Experimental animal care, cell fusion, and 
generation of the monoclonal hybridoma cell line 95J10 were 
performed by Diabor Ltd, Oulu, Finland.
Other antibodies used were R254 (a rat mAb against mouse 
perlecan; a generous gift of Dr J. van den Bom), M215 (a mouse 
mAb against the core protein of HSPG isolated from human 
GBM [3]), and K42 (a rabbit antiserum recognizing HSPG from 
the human and murine GBM [9]).
Immunological methods. SDS/PAGE and im mu nob lot 
analyses were carried out following standard procedures [30], 
All samples were denatured by boiling in the presence of 2- 
mercaptoethanol prior to loading onto a homogeneous 5% poly­
acrylamide gel Immunofluorescence and tissue distribution 
studies were performed with adult human tissue specimens ob­
tained during autopsy, snap-frozen in liquid nitrogen, and stored 
at -80°C until use. Cryostat sections of 2 \.im were attached to 
glass slides and treated with acetone for 10 min at 4QC for fixa­
tion. mAb M215 or 95J10 was applied as undiluted hybridoma 
supernatant. After 1 h incubation at 22°C, specimens were sub­
merged five times in fresh NaCl/Pj for washing. Bound primary 
antibody was detected by incubating with fluorescein-isothiocy- 
anate-conjugated sheep-anti-mouse immunoglobulins (30 min at 
22°C in the dark). After thorough washing with fresh NaCI/P;, 
the preparations were examined with a Leitz immunofluores­
cence microscope. For immunoelectron microscopy, kidney cor­
tex slices were fixed with periodate-lysine and paraformalde­
hyde, immersed in 2.3 M sucrose for cryoprotection and snap- 
frozen in liquid nitrogen. Staining of peroxidase-conjugated an­
tibody complexes was performed following standard protocols 
[34] and the sections were postfixed in Epon 812. Thin sections 
were examined with a Jeol 1200 EX electron microscope.
Northern hybridization. A multiple human tissue northern 
blot (Clontech Laboratories Inc.) was treated according to the 
supplier’s protocol with an antisense probe homologous to exon
3 of perlecan (S'-AAGTCCCCGCTGCCCAGGTCCCCACTG- 
CCCAGGTCGT-3') [20]. This exon is a prerequisite for the
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Fig. 3. Imimmofliioreseence detection of heparan sulfate proteoglycans in the human renal cortex. Cryosec t ions  were  s ta ined for per lecan (A, 
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Fig. 7. Northern blot analysis of mRNA of various human tissues.
Poly(A)-r ieh m R N A  isolated from heart ( I), brain (2), placenta (3), lung 
(4), l iver (5), skeletal  muscle  (6), kidney (7), and pancreas  (8) was h y ­
bridized with a perlecan-specif ic probe and washed  stringently.  The  bot­
tom panel  show s  a control  hybridizat ion with a / j -act in-specific probe to 
indicate differences in total m R N A  content.
endornysium that surrounds the skeletal muscle fibers, the capil­
laries, an artery, nerve fibers with a myelin sheath, and perineu­
rium (bundles are surrounded by connective tissue). In contrast, 
in Ab M215 s t ai tied o n 1 y t h e c a pi 11 ari e s (Fi g. 51). In c e reb ru m, 
95J 10 strongly stains veins in the cerebral cortex, the arteries, 
and the capillaries. In the same tissue, mAb M215 only stains 
t h e c a pill ari e s (Fig. 5J). I n al 1 cases, th e spec i fi c i t y o f t h e stain­
ing was checked by parallel incubations without the primary an­
tibody.
The results obtained by immunohistochemistry suggest the 
occurrence of two different GBM-associated HSPG species. 
Could the observed differences be based on different epitope
accessibilities in vivol To exclude this possibility, preparations 
of HSPG isolated from the human GBM and from the mouse 
EHS tumor were analyzed by western blotting (Fig. 6). The EHS 
tumor is known to produce large amounts of perlecan. Using a 
rabbit polyclonal antiserum (K42) that recognizes both murine 
and human GBM-HSPG [9], no staining of EHS-HSPG was de-
izave identical results (data notr : \ /  >  r  /  ;  i
shown). As a control for the transfer of EHS-HSPG to the blot, 
an identical treatment with a rat mAb against mouse perlecan 
resulted in a marked staining of EHS-HSPG, mAb 95J10 could
not be used for this purpose, since it is specific lor human per­
lecan. The specificity of antiserum K42 for GBM-HSPG, with­
out any cross-reaction with perlecan, confirms that the two
Perlecan splice variants occur in brain, placenta and 
skeletal muscle but not in kidney. Elucidation of the perlecan 
gene structure showed the theoretical possibility of alternative 
splicing [ 16. 17, 20], Interestingly, the occurrence of splice vari­
ants would result in the expression of perlecan isoforms. We 
therefore investigated the occurrence of perlecan splice variants 
by northern blotting (Fig. 7), The full size messenger RNA (ap­
proximately 14 kb) was detected in heart, placenta, skeletal mus­
cle, kidney and pancreas, but was hardly or not at all present in 
brain, lung, and liver. Interestingly, a smaller size mRNA species 
was detected in brain (2.5 — 2.6 kb), placenta (1.9 kb and 6.4- 
6.7 kb) and skeletal muscle (3.1 — 3.3 kb). The significance of 
these molecules is not clear. In the kidney, however, we could 
not distinguish anv splice variants.
As the presence of strongly anionic HSPGs is important to 
maintain the selective permeability of the GBM, the identifica­
tion of perlecan as a basementmiemhrane-associated HSPG has 
provoked many investigators to study perlecan expression levels 
during nephropathy. We used mAb 95J10, directed against 
amino acids 22 — ¿decan, to analyze the distribu­
tion of perlecan in the glomerulus in more detail. The staining 
pattern of 95J10 in indirect immunofluorescence is in agreement
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with other studies performed with mAbs raised against recombi­
nant fragments from domain HI of perlecan [24, 25], and with a 
polyclonal antiserum against perlecan from the EHS-tumor [11]. 
However, the exact localization o f perlecan in the G B M  can 
hardly be deduced from immunofluorescence microscopy 
studies. Our results from iminunoeieetron microscopy indicate 
that perlecan is present in the G B M , but only on the endothelial 
side. Moreover, perlecan is distributed in a non-homogenous 
pattern and many segments ol the G BM  were not stained by 
95J10. Therefore, charge-selective properties of the GBM  can­
not be ascribed to the anionic charge of perlecan alone.
The expression pattern of perlecan is in marked contrast to 
that observed with M215, a previously described mAb against 
HSPG isolated Irom die G B M  [3|, This HSPG is less widely 
distributed than perlecan, as shown by indirect immunofluores­
cence on multiple human tissues. In the kidney, this antibody 
predominantly stained the G B M  in a linear manner. Similar re­
sults were obtained with other monoclonal and polyclonal anti­
bodies raised against GBM-HSPG, and with a mAb that recog­
nizes an epitope on the HS chain [5, 8 , 9]. The homogenous 
distribution of this HSPG within lhe GBM  was confirmed by 
iminunoeieetron microscopy.
Our results indicate that two immunologically unrelated 
HSPG species are present in the G BM . This conclusion is based 
on the following considerations. Firstly, the anti-HSPG antibod­
ies 95J10 and M215 show a clearly different distribution in hu­
man tissues. Comparing the staining patterns of 95J10 and 
M215, it is of importance that both antibodies are directed 
against the core proteins. The exact composition of the glycos- 
a mi nog ly can residues is not solely dependent on the nature of 
the core protein, but is also influenced by the cellular environ­
ment in which they are synthesized and modified, Secondly, we 
demonstrated that a polyclonal antiserum against GBM-HSPG 
does not cross-re act with perlecan. Thirdly, observations from 
other groups also support the presence of multiple extracellular 
HSPG species in the glomerulus. In one of these investigations, 
proteoglycan synthesis was studied in cultures of three cell types 
from calf glomeruli. Epithelial cells excreted immunologically 
distinct HSPG components (approximately 300 kDa) as com­
pared to endothelial and mesangial cells, which produced a per- 
iecaivtype HSPG (molecular mass 500 kDa) [35). Another study 
supported the synthesis of perlecan-like HSPG by cultured rat 
mesangial cells |36|. Finally, partial amino acid sequences of 
HSPG isolated from bovine and human kidney also supported 
the presence of HSPG species that are unrelated to perlecan
[37, 381.
After hybridization of kidney mRNA, only the full-length 
perlecan transcript could be distinguished (Fig. 7). Although m i­
nor differences in m RN A  length cannot be detected by this 
method, such small rearrangements could not explain the altered 
immunoreactivity towards mAbs with different domain speci- 
icities (this study and [24, 251). Heparan-sulfate-carrying splice 
isoforms of perlecan could not he missed through the choice of 
the probe, because the corresponding exon is required for the 
presence of IIS chains |20|. Therefore, the production of 
multiple HSPGs in the G B M  is not mediated by alternative 
splicing of perlecan. 'Phis indicates that a different gene is in­
volved.
The availability of the recombinant perIecan-(24—404)-pe 13- 
tide and mAb 95J10 could be of value in determining the func­
tional properties of the individual domains of the perlecan core 
protein. The ultrastructural localization of perlecan in the GBM  
suggests that its role in the maintenance of selective glomerular 
permeability is more modest than was initially assumed. The 
presence of an additional HSPG, which is unrelated to perlecan, 
may open a new direction for investigating the structural basis
of charge-selective GBM  permeability. The unidentified HSPG 
that is highly expressed in the G B M  may play an important role 
in renal function.
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